You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.

Preprint
Review

Human Milk Oligosaccharides: 2’-fucosyllactose (2’-FL) and Lacto-N-neotetraose (LNnT) in Infant Formula

Altmetrics

Downloads

1287

Views

449

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

23 July 2018

Posted:

23 July 2018

You are already at the latest version

Alerts
Abstract
Introduction The authors reviewed the published evidence on the presence of oligosaccharides in human milk (HMO) and their benefits in in vitro and in vivo studies, as well as to evaluate published data on the addition of some of HMOs to infant formula. Method PubMed was searched from inception to April 2018 Results The presence of HMOs is a dynamic process, determined by many factors such as duration of lactation, environmental and genetic factors. HMOs may support immune function development and provide protection against infectious diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation of the gut microbiota, including the stimulation of the bifidobacteria. Only a few of the many HMOs can be made industrially, and are added to infant formula. They have been shown to be safe and well tolerated, including normal growth and a trend towards health benefit. Conclusions HMOs are one of the major differences between cow’s milk and human milk , and evidence indicates that these components do have a health promoting benefit. The addition of one or two of these components to infant formula is safe, and brings infant formula closer to human milk.
Keywords: 
Subject: Medicine and Pharmacology  -   Pediatrics, Perinatology and Child Health
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2024 MDPI (Basel, Switzerland) unless otherwise stated